Work

Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis

Year: 2023

Type: article

Source: Multiple Sclerosis and Related Disorders

DOI: 10.1016/j.msard.2023.104733

Authors: Vinícius Oliveira Boldrini, Simone Mader, Tania Kümpfel, Edgar Meinl

Institutions: Universidade Estadual de Campinas (UNICAMP), Brazilian Institute of Neuroscience and Neurotechnology, Institut für Klinische Neuroimmunologie, Ludwig-Maximilians-Universität München, LMU Klinikum

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Clinical Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4366981225

FWCI: 1.778

Cites: 18

Cited by: 11

Related to: 10